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paclitaxel-eluting stents for the treatment of femoro-popliteal (FP)
occlusive disease. However, the external validity of trial results may
be restricted to less complex FP lesions, and limited data on outcomes
of pacliaxel-eluting stents in real world practice have been published.
METHODS This study is a retrospective analysis of data of all the
patients who received Zilver PTX for FP lesion from February 2013
to October 2014 at MedStar Washington Hospital Center in Washing-
ton, DC. The primary endpoint of this study was primary patency,
deﬁned as a peak systolic velocity ratio < 2.0 by Doppler ultrasound,
or angiographic diameter stenosis < 50%, or freedom from clinically
driven target lesion revascularization.
RESULTS A total of 78 patients received Zilver PTX for FP lesions
in the pre-speciﬁed time period. Of them, 63 had follow-up data
and were included in this study. The mean patient age was
66.39.4 years, and 57.1% of the patients were men. Participants
had a high prevalence of diabetes (49.2%), hypertension (93.7%),
hyperlipidemia (93.7%), previous coronary revascularization
(52.4%), or previous peripheral arterial disease (77.8%). Critical limb
ischemia was present in 25.4% of the patients, Trans-Atlantic Inter-
Society Consensus (TASC) class C or D in 76.2%, in-stent restenosis
(ISR) in 36.5%, and total occlusion in 69.8%. The mean lesion
length was 218.9128.3mm, the mean number of stents was
2.021.0, and total stent length was 189.0128.5 mm. Mean follow-
up was 270.4190.3 days. Primary patency rate at 1 year was 66.7%
by Kaplan-Meier survival curve. When compared with patients with
primary patency at follow-up, those with an adverse outcome had
higher prevalence of TASC II class C or D lesions (100% vs. 68.8%,
p¼0.013), and were more likely to have ISR (66.7% vs. 27.1%,
p¼0.012), longer lesion (291.3138.7 vs. 195.7117.1, p¼0.011), and
incomplete coverage of the lesion (full coverage of lesions: 40% vs.
77.1%, p¼0.011).
CONCLUSIONS Post marketing use of Zilver PTX for the treat-
ment of FP lesions is associated with lower patency rates compared
with clinical trial data. This may be related to the high prevalence of
TASC II class C or D lesions and ISR in real world practice. Future
studies should be more representative of contemporary clinical
practice.
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BACKGROUND Arteriovenous ﬁstula (AVF) dysfunction caused by
venous intimal hyperplasia persists as a signiﬁcant threat to AVF long-
term patency. Beyond conventional vascular planimetry we aim to
evaluate the use of cell proliferation markers in neointima in a swine
model of AVF.
METHODS Femoral AVF were surgically performed in nine swine by
anastomosis. AVFs were followed for 3(n¼3) and 90(n¼6) days. At
termination, AVFs were harvested and histological and planimetric
analysis was performed. Immunohistochemistry for cellular prolifer-
ation was performed at the anastomosis levels as well as the arterial
(A) and venous (V) anastomosis side.
RESULTS At 3 days, AVF displayed matching dimensions between V
and A with a vascular area of 13.24.3mm2 in A and 15.19.4 mm2 in
V. By 90 days, the vascular area on V increased by approximately 4-
fold (58.642.5 mm2) while A increased by less than 3-fold
(37.39.4 mm2). These planimetric ratios remained consistent in the
proximal A and distal V at 3 (A¼14.34.1 mm2;V¼36.814.8 mm2) and
90 days (A¼40.212.8 mm2;V¼68.628.2 mm2). At 3 days, percent
area of stenosis (%AS) at the anastomosis was minimal (A¼1.81.5%;
V¼56.1%). However at 90 days, V demonstrated markedly increased
%AS (21.916.5%) compared to A (6.92.9%), reﬂecting V being arte-
rialized. As expected, cell proliferation counts were high at 3 days
evidenced by a high Ki67 index in V (159.2134.7 cells/mm2) and
highest values were recorded in the V distal outﬂow side. Ki67 counts
signiﬁcantly decreased at 90 days (35.222.4 cells/mm2).CONCLUSIONS Proliferation markers (Ki67) provide valuable assess-
ment of vascular response. The AVF swine model provides an ideal
scenario where conventional planimetry data describes the structural
outcome while proliferative markers provide a dynamic picture of the
biological vascular response.
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BACKGROUND There are serious risks associated with untreated pe-
ripheral and visceral arterial thromboembolism. The Penumbra/Indigo
System is a novel, highly trackable and efﬁcient aspiration system in
the peripheral vasculature. Reported herein are the initial results from
the PRISM trial, the ﬁrst multicenter study designed to obtain safety
and effectiveness data in conﬁrmed peripheral or visceral artery
occlusion.
METHODS A total of 55 patients have been enrolled in this retro-
spective trial. In cases of failed thrombolysis, acute ischemia, or pa-
tients with distal emboli due to a prior intervention, thrombectomy
using the Penumbra/Indigo System was implemented. The primary
sites of occlusion were the popliteal (38.9%), peroneal (9.3%), super-
ﬁcial femoral (18.5%), posterior tibial (7.4%), profunda femoris (3.7%),
superior mesenteric (3.7%), anterior tibial (9.3%), renal (3.7%), com-
mon femoral (1.9%), and brachial (1.9%) arteries.
RESULTS The mean patient age was 70.4  12.9 years. At baseline,
96.1% (49/51) patients reported an angiographic TIMI score of 0-1, and
4 patients were unable to be assessed. Before any intervention was
performed, 37.7% (20/53) of patients received only thrombolytic
therapy, 9.4% (5/53) received only mechanical intervention, 7.5% (4/
53) received both therapies, and 45.3% (24/53) had no prior treatment
and were treated with the Penumbra/Indigo Systems as frontline.
Median time from symptom onset to procedure was 5.0 days (IQR 2.0-
24.0). Post-procedure, 96.1% (49/51) of patients were successfully
revascularized to TIMI 2 (39.2%) or TIMI 3 (56.9%). Six patients had
SAEs, none related to the device.
CONCLUSIONS Experience with the Penumbra/Indigo System dem-
onstrates that using thrombo-aspiration for peripheral and visceral
thromboembolism can lead to promising results in safety and effec-
tiveness. This validates possible use across a wide range of applica-
tions in the peripheral vasculature.
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BACKGROUND There are limited data on outcomes of stent-based
treatment of femoropopliteal peripheral artery disease (PAD) in pa-
tients with diabetes mellitus (DM).
METHODS Consecutive patients between January 2006 and March
2015 enrolled in the observational Excellence in Peripheral Artery
Disease (XLPAD) registry (NCT01904851) were analyzed. Index limb
procedures of patients with stent implants were included in the
analysis. Outcomes tracked were major adverse limb events (MALE;
target limb revascularization, surgical revascularization, and un-
planned above-ankle amputation in target limb) and major adverse
